ACE-2494 / Merck (MSD) - LARVOL DELTA

Novel ActRIIB ligand trap increases muscle mass and improves bone geometry in a mouse model of severe osteogenesis imperfecta. (PubMed, Bone) - "However, treatment of Col1a1mice with ACE-2494 was associated with significant gain in muscle mass, significantly improved bone length and bone geometry, but no significant treatment effect was found on bone mass or bone mechanical properties. Thus, our data indicate that activin A/myostatin neutralizing antibody ACE-2494 is effective in stimulating muscle mass, bone length and diaphyseal bone growth but does not correct bone mass phenotype in a mouse model ofdominant OI."

Journal • Preclinical • Genetic Disorders

A Study of ACE-2494 in Healthy Subjects (clinicaltrials.gov) - P1; N=48; Completed; Sponsor: Acceleron Pharma, Inc.; Active, not recruiting ➔ Completed; Trial completion date: Oct 2019 ➔ Jun 2019

Clinical • Trial completion • Trial completion date

A Study of ACE-2494 in Healthy Subjects (clinicaltrials.gov) - P1; N=48; Active, not recruiting; Sponsor: Acceleron Pharma, Inc.; Trial completion date: May 2019 ➔ Oct 2019; Trial primary completion date: May 2019 ➔ Aug 2019

Clinical • Trial completion date • Trial primary completion date

Acceleron discontinues development of phase 1 molecule ACE-2494 (Businesswire) - "Acceleron Pharma...announced it is discontinuing development of ACE-2494, a systemic muscle agent the company had been studying in a Phase 1 healthy volunteer trial for the potential treatment of neuromuscular disorders."

Discontinuation

A Study of ACE-2494 in Healthy Subjects (clinicaltrials.gov) - P1; N=48; Active, not recruiting; Sponsor: Acceleron Pharma, Inc.; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed